Overall, these results indicate that knockdown of DHX9 inhibits p65 activation, inflammatory factor expressions, and the transcriptional activity of p65-RNA Polymerase II complex in PBMCs from CAD patients. The gene discussed is DHX9; the disease is coronary artery disorder.